Pfizer sought an immersive way to educate patients and providers about a new drug developed for the treatment of Alopecia Areata, a condition affecting roughly 2% of the population. Understanding a new drug’s mechanism of action is essential, not only for patients but also for healthcareprofessionals who may need a refresher on the disease.

Debuted at CES 2023, the Pfizer Mediverse is an immersive VR space for doctors and patients to understand a range of conditions and their treatments.